key: cord-0703254-np1iymc3
authors: Yu, Lili; Zhang, Xiaoying; Ye, Sarah; Lian, Hongkai; Wang, Hui; Ye, Jianping
title: Obesity & COVID-19: mechanistic insights from adipose tissue
date: 2022-03-09
journal: J Clin Endocrinol Metab
DOI: 10.1210/clinem/dgac137
sha: e44332c5d990a6cff2fc2d0cff9ebff427601d77
doc_id: 703254
cord_uid: np1iymc3

Obesity is associated with an increase in morbidity and mortality from COVID-19. The risk is related to the cytokine storm, a major contributor to multiorgan failure and a pathological character of COVID-19 patients with obesity. While the exact cause of the cytokine storm remains elusive, disorders in energy metabolism has provided insights into the mechanism. Emerging data suggest that adipose tissue in obesity contributes to the disorders in several ways. First, adipose tissue restricts the pulmonary function by generation of mechanical pressures to promote systemic hypoxia. Second, adipose tissue supplies a base for SARS-CoV-2 entry by overexpression of viral receptors (ACE2 and DPP4). Third, impaired antiviral responses of adipocytes and immune cells result in dysfunction of immunologic surveillance as well as the viral clearance systems. Fourth, chronic inflammation in obesity contributes to the cytokine storm by secreting more pro-inflammatory cytokines. Fifth, abnormal levels of adipokines increase the risk of a hyper-immune response to the virus in the lungs and other organs to enhance the cytokine storm. Mitochondrial dysfunction in adipocytes, immune cells and other cell types (endothelial cells and platelets, etc.) is a common cellular mechanism for the development of cytokine storm, which leads to the progression of mild COVID-19 to severe cases with multiorgan failure and high mortality. Correction of energy surplus through various approaches is recommended in the prevention and treatment of COVID-19 in the obese patients.

COVID-19 (coronavirus disease 2019) is an infectious diseases caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2) identified in 2019. As of Feb. 1st, 2022, the virus and its variants have infected more than 377 million people with 5.7 million deaths worldwide (https://coronavirus.jhu.edu/map.html). The COVID-19 pandemic has generated a huge challenge to the global healthcare community due to the high mortality rate. Although the infection and mortality have been effectively reduced by virus-targeting vaccinations, the threat remains serious as current vaccinations may lose efficacy to emerging mutant strains of virus, and a large portion of world's population remains unvaccinated. It is generally accepted that multiorgan failure is a major cause of the high mortality rate in COVID-19 with cytokine storm as the primary underlying event (1, 2) .

Obesity is a well-established risk factor for severe COVID-19 with high mortality (3, 4) , which was first reported in April 2020 and currently supported by epidemiological data from the World Health Organization (WHO) (https://ourworldindata.org/). Based on WHO data in 2016, obesity has become a pandemic, with 39% of adults (age>18 years) being overweight or obese worldwide, leading to 4.7 million premature deaths each year (https://www.who.int/). The combination of the COVID-19 and obesity pandemics has resulted in a significant increase in the death rate in COVID-19 patients. The underlying mechanism linking obesity to the high death rate remains to be established, however, the chronic inflammation and tissue structure changes derived from obesity appear to be the major factors. For example, obesity may reduce the function of the respiratory system by complications, such as asthma, obstructive sleep apnea (OSA), and chronic obstructive pulmonary disease (COPD) (5) (6) (7) . The same applies to the H1N1 influenza virus infection (7) .

In obesity, adipose tissue expansion induces multiple structural and functional changes in the body, which contribute to the development of severe COVID-19 (8, 9) (Figure 1 ). The cellular and molecular events of adipose tissue dysfunction leading to sever COVID-19 will be discussed in this review.

Obesity, defined by a body mass index (BMI) over 30 kg/m 2 , increases morbidity and mortality of COVID-19. The relationship was first reported by a French group in a study with a small sample size, in which obese patients (BMI greater than 35 kg/m 2 ) had a 7.36-fold increase in need for invasive mechanical ventilation over the lean patients (BMI below 25 kg/m 2 ). The first large-scale clinical study of 5,700 hospitalized COVID-19 patients in New York, USA, provided subsequent support that the most common comorbidities were obesity (41.7%), hypertension (56.6%) and A c c e p t e d M a n u s c r i p t 4 diabetes (33.8) (10) . This relationship is consistently supported by later studies. A retrospective study containing 150 patients in China showed that a larger proportion of obese patients (33.3%) progressed to severe COVID-19 relative to the non-obese patients (11) . Another retrospective study of 1,158 patients in Kuwait also found obesity as an independent risk factor for severe COVID-19 (12) . A cohort study in the United Kingdom reported a liner increase in hospitalization for COVID -19 patients with high BMI (13) . A study of 1,795 patients in Boston, USA, found a relationship between high BMI, longer hospital stays, and ICU admission rates in patients with acute respiratory distress syndrome (ARDS) syndrome (14) . The relationship is also supported by a recent systematic review and meta-analysis that covered a total of 45,650 patients from 30 studies with obesity and 3 controlled studies with visceral obesity. Obesity not only aggravates COVID-19, but also promotes the occurrence of the entire course of COVID-19 (15) . The impact of obesity is particularly pronounced in patients over the age of 60 (16) . The relationship between COVID-19 and obesity is considered as "a Pandemic Within a Pandemic" (17) . These reports consistently support that obesity increases the risk of severe COVID-19.

Several factors have been proposed in the mechanism of severe COVID-19 in obese patients, which include anatomical changes and functional alterations derived from obesity ( Figure 1 ).

Hyperlipidemia in obesity increases blood viscosity, which creates a prothrombotic environment to impair blood circulation. Thrombotic microangiopathy, arterial thrombosis and venous thrombosis are major pathological changes seen in blood vessels of severe COVID-19 patients (18) . OSA, a common complication in obesity with difficulties in breathing, causes systemic hypoxia leading to severe hypoxemia following lung injury in COVID-19 patients. The hypoxemia may contribute to severe COVID-19 through cytokine storm (19) . Other complications of obesity that may contribute to severe COVID-19 include hyperglycemia (20) , type 2 diabetes mellitus (21), dyslipidemia (22) , hypertension (23), atherosclerosis (24) and vitamin D deficiency (25) . Obesity may dampen the innate and adaptive immune responses to virus, which contributes to viral spread across organs and failure of vaccinations (26) . Obesity contributes to vaccination failure through induction of senescence in immune cells, such as natural killer (NK) cells (27) , cytotoxic T cells (28) and B cells (29) . These factors will not be extensively discussed here as they have been well documented in other reviews (30-32).

White adipose tissues include subcutaneous and visceral fat depots. Excessive subcutaneous adipose tissue around the chest and abdomen restricts lung expansion during respiration. Lung activity is dependent on expansion of the chest cavity and intra-abdominal cavity. The subcutaneous A c c e p t e d M a n u s c r i p t 5 fat depots physically limit chest cavity expansion, which decreases respiratory vital capacity to limit pulmonary function (7) .

The visceral depots are mainly located in the abdominal cavity, which include omental, mesenteric, and retroperitoneal spaces. In obesity, there is huge expansion in visceral adipose tissue in addition to the subcutaneous fat. These fat depots increase peritoneal cavity pressure thereby restricting diaphragm movement and limiting lung activity. Both subcutaneous and visceral fat depots have been assessed in COVID-19 patients, and visceral fat depots were proven to increase the risk for severe COVID-19 (33) . Therefore, visceral fat accumulation may serve as a predictive factor for intensive care admission in COVID-19 since fat depots contribute to pulmonary dysfunction and lung failure through the mechanical effects (34) . In addition, visceral fat depots may contribute to severe COVID-19 through biological activities such as production of pro-inflammatory cytokines, which may be exacerbated by the virus infection contributing to the progression to cytokine storm.

Epicardial fat is ectopic fat deposition surrounding the myocardium and may fuel COVID-19induced cardiac injury and myocarditis (35) . Epicardial fat is a unique fat depot with multifaceted features and induces local and systemic physiological effects (36) . Epicardial fat quantified from chest CT are independently associated with the extent of pneumonia and adverse outcomes in patients with COVID-19, supporting their application to clinical risk stratification (37) . The fat volume of epicardial fat is a perfect indicator for severe COVID-19 in some obese patients (38) .

The SARS-CoV-2 virus has a non-segmented, positive single-stranded RNA genome with approximately 30,000 bases. The genome encodes four structural proteins, including the surfacelocated trimetric spike (S) protein, membrane (M) proteins, the nucleocapsid (N) combined with the RNA genome and the envelope (E) proteins (39) . SARS-CoV-2 is an obligate intracellular microorganism that uses the RNA genome as a template to encode the replicase and structural proteins for self-replication. The virus typically infects host cells by interacting with cell surface proteins, such as angiotensin-converting enzyme (ACE) and dipeptidyl peptidase 4 (DPP4), to enter the host cell and nucleus ( Figure 2 ). This propagation can interfere with normal cellular activities such as protein synthesis and energy metabolism, causing subcellular organ damage and ultimately cell death. Adipose tissue is a reservoir for other virus including influenza A virus, human adenovirus AD-36 and cytomegalovirus (40) . Adipose tissue expresses ACE and DPP4 for SARS-CoV-2 virus infection, and the increased volume of adipose tissue in obesity may serve as a larger reservoir for

A c c e p t e d M a n u s c r i p t 6 The first virus receptor found in adipose tissue is ACE2. SARS-CoV-2 uses the viral spike (S) protein for host cell entry. The protein consists of two subunits with distinct functions. The surface subunit (S1) binds to ACE2 on the host cell membrane, whereas the transmembrane subunit (S2) facilitates fusion of the viral membrane with the host cell membrane (41) . The spike protein binds to ACE2 through the receptor-binding domain (RBD) region (42) . Transmembrane protease serine 2 (TMPRSS2) cleaves the spike protein to facilitate the fusion of SARS-CoV-2 and host cell membranes.

Because of this, the spike protein is a major target in exploration of anti-virus vaccines worldwide.

Interestingly, ACE2 is expressed by adipocytes in the adipose tissue (43, 44) . ACE2 gene expression is higher in the visceral and subcutaneous adipose tissues than lung tissue in the human body according to gene expression profile (44) . Moreover, an increase in transcription, expression, and enzymatic activity of ACE2 was observed in adipose tissue in obese mice (45) . A study of a large cohort of obese patients with COVID-19 revealed serum ACE2 elevation (46) . The high adipose ACE2 expression was reported with more mortality in obese COVID-19 patients (44) . These studies suggest that adipose tissue may contribute to the severity of COVID-19 through expression of high expression of ACE2 (47) . However, mechanism of the ACE2 action remains unknown.

Glucose may increase the binding activity of ACE2 to SARS-CoV-2 in obesity (48) . Glycosylation of ACE2 and the viral spike protein under hyperglycemic conditions was found to increase the affinity and interaction of the two proteins promoting virus entry into host cells (49) (50) (51) .

Glycosylation of the human ACE2 receptor contributes substantially to virus binding. The glycan at the N322 site in ACE2 interacts tightly with the receptor-binding domain of the spike protein to strengthen the complex (50) . Cryo-electron microscopy indicates that the viral spike protein is extensively glycosylated to facilitate binding to the ACE2 receptor (49) . Uncontrolled hyperglycemia might induce glycosylation of ACE2 and the spike protein of SARS-CoV-2, however, the stable glucose adducts require long-term exposure to hyperglycemia. The glycosylation effect remains to be Based on bioinformatic and protein docking models, the spike protein of SARS-CoV-2 binds to DPP4 with a high affinity (57) . High expression of DPP4 in obese patients may facilitate SARS-CoV-2 viral entry into adipocytes resulting in a strong inflammatory immune response. Adipose tissue is also a significant source of circulating soluble DPP4 (58) . A high level DPP4 secretion was demonstrated in adipose tissues of obese patients. Interestingly, soluble DPP4 may serve as a receptor to block SARS-CoV-2 infection activity, however, it may also protect the virus (59, 60) . DPP4 is a well-established enzyme in the degradation of glucagon-like peptide-1 (GLP-1), a gut hormone used for treatment of type 2 diabetes (61). Up-regulation of DPP4 in obesity may reduce the anti-inflammatory activity of GLP-1 contributing to adipose tissue inflammation and the pathogenesis of cytokines storm (62) . It has been suggested that the use of DPP4 inhibitors, such as gliptins, in patients with COVID-19 even without type 2 diabetes, may be protective against virus entry and the development of cytokine storm (59) . In summary, the interaction between DPP4 and SARS-CoV-2 may promote COVID-19 disease severity, but infection and disease progression may be blocked by a DPP4 inhibitor. This point was supported by a systematic review and meta-analysis of 4,477 patients from 9 studies, in which DPP4 inhibitors were found to significantly reduce the mortality rate of COVID-19 patients (65) . In contrast, an epidemiological study showed that DPP4 inhibitor did not affect hospitalization of COVID-19 patients in Italy (66) . In addition, a meta-analysis including six observational studies with 1,531 COVID-19 patients concluded that use of DPP4 inhibitors provided neither benefit or side effect in the patients (67) . While, a multinational retrospective cohort study suggests that use of DPP-4 inhibitors may improve COVID-19 outcomes for patients with T2DM (68).

The effect of DPP4 inhibitors needs more investigation in COVID-19 patients.

The benefits of GLP-1 receptor agonists (GLP-1RAs) in the control of COVID-19 are more consistent. As another type of glucose-lowering agents, GLP1RAs exhibit benefits in the treatment of COVID-19 patients with and without diabetes mellitus type 2 (T2DM) (69) . One meta-analysis reported that GLP-1RAs did not increase the risk for respiratory tract infection, pneumonia, or acute respiratory distress syndrome in patients with T2DM and cardiovascular comorbidities (70) . In addition, another meta-analysis spanning 9 studies with a total of 19,660 diabetic patients with COVID-19 found that pre-admission use of GLP-1RAs reduced mortality (69) . These results suggest a A c c e p t e d M a n u s c r i p t 8 benefit of GLP-1RAs in the treatment of COVID-19. However, more randomized clinical trials are required to confirm this conclusion.

The antiviral immune response requires the innate immune system (including natural killer cells (NK), dendritic cells (DC), monocytes, macrophages, NKT cells) and the adaptive immune system (T and B cells) (71, 72) . Coordination between the two systems is essential in the control of viral dissemination (73, 74) . The innate immune system responds first with recognition of the virus by tissue-resident dendritic cells and subsequent recruitment of NK cells, monocytes, macrophages, and NKT cells to clear the virus. In adipose tissue, this antiviral response is regulated by adipocytes (75) .

There is immune dysfunction in severe COVID-19, which is characterized by reduced interferon production from innate immune cells in the early stage, delayed adaptive immune responses, and over production of cytokines in the late stage (76) . This dysfunction is enhanced in obese COVID-19 patients, in which the immune system is unable to generate an effective anti-viral response due to obesity (77) . Immune dysregulation in obesity is multifactorial and metabolism disorder in the immune cells is an important factor. Immune cells use their reserve capacities to gain extra energy from glucose, fatty acids, and ketones in the response to viral and bacterial pathogens (78, 79) . The extra energy is required for the production of signal mediators and effector molecules to control the infection. However, this metabolic reserve is impaired in obesity due to energy surplus, which leads to mitochondrial dysfunction in immune cells (discussed below). The cytokines produced by immune cells serve as signals in the coordination of immune responses and in the maintenance of body energy homeostasis (80) . However, this activity is reduced by the chronic inflammation and energy surplus in obesity, which make the immune cells (Macrophages, NK cells, iNKT cell, T cells and B cells) fail to operate properly as reflected in failure of the antiviral immune response and tissue damage from the cytokine storm in severe COVID-19.

Adipocytes secrete type I interferon (IFN) in response to viral infection, but they may also serve as host cells for SARS-CoV-2 (81) (82) (83) (84) . IFNs are the major cytokines in antiviral immunity (85) . 

Immune cells are subject to metabolic reprogramming in the circulation, lymph nodes, and adipose tissue in obesity. The metabolic changes decease the activities of NK, iNKT, T and B cells, which compromise the antiviral immune response in COVID-19.

NK cells are effector lymphocytes of the innate immune system, which recognize and destroy infected cells through production of cytotoxic molecules, such as granzymes and perforins, fragment receptor ligand (FasL), and TNF-related apoptosis-inducing ligand (TRAIL). NK cells recognize infected cells marked with antibodies through Fc receptors and destroy them through antibody-dependent cellular cytotoxicity (ADCC) (Figure 4 ). In obesity, the number of NK cells is increased in visceral adipose tissue due to local cell proliferation (90)however, NK cells activity is reduced (91) .There is reduced expression of activating receptors KIR2DS4 and NKp46, increased expression of inhibitory receptor NKG2A, and decreased TRAIL expression on NK cells (92) . This suppression is related to the A c c e p t e d M a n u s c r i p t energy metabolism disorder in NK cells in obesity (27, 93) . NK cell activity is highly dependent on glycolysis, which is inhibited in obesity by the increased activity of peroxisome proliferator-activated receptors (PPARs) (27) . Glycolysis inhibition together with other changes, such as excessive exposure to FFA and IL-6, may inhibit NK cell production of granzyme B and perforin in obesity (94) . In summary, NK cell function is reduced in obesity through metabolic reprogramming and glycolysis inhibition. 

Several studies suggest significant roles of adipokines/hormones in severe COVID-19 (107) . Adiponectin is one of the most abundant proteins in the serum. Its level is reduced in obesity. In contrast to leptin, adiponectin has an anti-inflammatory activity, which induces expression of antiinflammatory cytokine IL-10 and inhibits expression of pro-inflammatory cytokines like TNF-α and IL-

A c c e p t e d M a n u s c r i p t 12 screening glucoregulatory hormones revealed that adiponectin level is also reduced in the circulation of COVID-19 patients (81) . Hamsters infected with SARS-CoV-2 exhibited a strong antiviral response in adipose tissue with a reduced expression of adiponectin (81) . The exact role of adiponectin remains to be investigated in COVID-19 although it is considered beneficial in the control of severe COVID-19 (112) .

Mitochondria produce 90% of the ATP and ROS in cells for execution of various cellular activities (113) . According to classical biochemical principles, ATP is produced on demand and intracellular ATP levels are maintained at a set point between 1.5-2.5 mM in a cell type-dependent manner. However, over supply of energy materials including glucose, fatty acids, and amino acids in obesity leads to "mitochondrial overheating" and ATP overproduction in cells (114) . The extra ATP causes mitochondrial dysfunction by inhibiting mitochondrial biogenesis and mitophagy, which are essential in the maintenance of the quality and quantity of mitochondria. Dysfunctional mitochondria predispose to more mtROS production, oxidative stress, and exposure of mitochondrial DNA (mtDNA) in the cytoplasm. mtROS and mtDNA both promote inflammatory responses and immune dysregulation ( Figure 6 ).

In the course of SARS-CoV-2 infection, oxygen supply is reduced in the peripheral tissues due to structural damage in the lungs by the viral infection. Hypoxia causes energy metabolism reprogramming in mitochondria with shift from oxidative phosphorylation towards glycolysis (113) .

The mechanism is related to activation of the hypoxia signaling pathway including the hypoxia inducible factor 1 (HIF-1). The metabolic reprogramming may lead to an increased production of mtROS and mtDNA through HIF-1 activation, which in turn promotes the inflammasomal activation for IL-1β and IL-18 release, all contributing to the pathogenesis of cytokine storm. The NLRP3

inflammasome, containing the pyrin domain-containing protein 3 (NLRP3), is activated by several mitochondrial ligands, such as mtDNA, ATP, and mtROS (115) . After NLRP3 activation, an adaptor protein of apoptosis-associated speck-like protein (ASC) recruits pro-caspase-1 to the inflammasome. Caspase-1 cleaves pro-IL-1β and pro-IL-18 to generate the mature cytokines for secretion ( Figure 6 ).

Mitochondrial DAMPs (mtROS and mtDNA) are important factors in the cell detection of infection. However, the pathway may cause an undesirable immune response resulting in unwanted inflammation in certain conditions, such as obesity. In obesity, mitophagy is defective leading to accumulation of damaged mitochondria and release of mitochondrial DAMPs into the cytosol.

A c c e p t e d M a n u s c r i p t 13 further enhanced in COVID-19. This may contribute to progression to severe cases with cytokine storm in obese COVID-19 patients.

The mitochondrial dysfunction may also contribute to cytokine storm through production of intermediate metabolites of the TCA cycle. One example is α-ketoglutarate (α-KG), which plays an important role in the pro-inflammatory response. α-KG is found to be elevated in macrophages after lipopolysaccharide (LPS) stimulation and plays a role in the production of cytokines. Elevation of α-KG levels have been reported in T cells in rheumatoid arthritis (116) . LPS levels in the circulation and α-KG levels in the liver of obese mice are elevated (117) , which supports a role of α-KG in the proinflammatory response in obesity. Succinate is another example of a proinflammatory metabolite of the TCA cycle. Succinate elevation promotes macrophage activation and production of proinflammatory cytokines (118) . Succinate is elevated in the circulation of obese mice and patients with T2DM and promotes inflammation through succinate receptor (SUCNR1) (119). In addition, protein modification by succinylation is another mechanism in the regulation of the inflammatory response. Therefore, the increased levels of mitochondrial metabolites (α-KG and succinate) may contribute to cytokine storm in the pathogenesis of severe COVID-19 in obese patients.

Given the strong impact of obesity in the immune system, obesity may negatively affect the treatment and prevention of COVID-19. To control the negative effects, weight loss is the first choice, which may be achieved through behavioral modifications including calorie restriction, physical activity, or exercise training.

Adequate nutritional status is an essential element for antiviral defense. In a systematic review, vitamins (A, C, D and E), omega 3 fatty acids, and minerals (zinc and iron) were found to be fundamental for an adequate antiviral immune response to SARS-CoV-2 (120). Obesity is recognized as a vitamin deficient state despite energy surplus. In particular, the prevalence of vitamin D deficiency is 35% greater in obese individuals (121) . Vitamin D deficiency also increases the risk of For COVID-19 patients with obesity, guidelines for supportive treatment and intensive care have been well established (125) . Efficacy of antiviral medication may be reduced in obese patients.

Hydroxychloroquine was reported to interfere with the replication cycle of SARS-CovV2 and reduce viral entry. However, recent studies did not show that hydroxychloroquine administration was associated with a significant reduction in the end point of incubation or death rate during COVID-19 treatment (126) . Lopinavir/ritonavir, inhibitors of 3-chymotrypsin-like protease that involves in viral ribonucleic acid processing, was previously used as the first line antiviral agent in the treatment of COVID-19. The medicines have side effects including lipodystrophy and hyperlipidemia. However, the efficacy of lopinavir/ritonavir has come into question as multiple studies did not find it to reduce mortality significantly (127) . The conclusion that lopinavir/ritonavir combination was no better than standard care in the treatment of COVID-19 patients still remains (128) . However, favipiravir shows promising efficacy in COVID-19 patients with improvement in clinical parameters such as length of hospitalizations and clinical recovery, although the results were not confirmed in some studies (127) .

In this case, antidiabetic agents such as DDP4 inhibitors, GLP-RA, and antiviral agents (e.g.

Favipiravir) are all considered for COVID-19 treatment.

In this review, we discuss mechanisms by which obesity contributes to the high mortality of Obesity induces mitochondria overheating to cause extra ATP production, which eventually results in mitochondrial dysfunction. Dysfunctional mitochondria predispose to more mtROS production and exposure to mtDNA. Mitochondrial ligands, such as mtDNA, ATP, and mtROS induces the activation of the NLRP3 inflammasome. After NLRP3 activation, an ASC adaptor protein recruitspro-caspase-1

Cytokine Storms: Understanding COVID-19

Global pandemics interconnected -obesity, impaired metabolic health and COVID-19

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Metabolic Syndrome and the Lung

Chair's Summary: Obesity and Associated Changes in Metabolism, Implications for Lung Diseases

Obesity Increases Mortality and Modulates the Lung Metabolome during Pandemic H1N1 Influenza Virus Infection in Mice

Targeting the Adipose Tissue in COVID-19

Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Obesity Is a Risk Factor for Greater COVID-19 Severity

COVID-19: Impact of obesity and diabetes on disease severity

Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom

Body mass index is associated with the development of acute respiratory distress syndrome

Obesity aggravates COVID-19: A systematic review and meta-analysis

The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis

SARS-CoV-2 and Obesity: "CoVesity"-a Pandemic Within a Pandemic

Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation

Potential influences of obstructive sleep apnea and obesity on COVID-19 severity

Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19

Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes. Front Endocrinol (Lausanne)

COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches

Severe Pulmonary Hypertension: An Important Sequel After Severe Post-Acute COVID-19 Pneumonia

Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives

COVID-19: Is there a role for immunonutrition in obese patient?

Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships

Metabolic reprogramming of natural killer cells in obesity limits antitumor responses

Altered Methylation Profile of Lymphocytes Is Concordant with Perturbation of Lipids Metabolism and Inflammatory Response in Obesity

DNA methylation is altered in B and NK lymphocytes in obese and type 2 diabetic human

Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities

COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances

Obesity and impaired metabolic health in patients with COVID-19

Visceral adipose tissue in patients with COVID-19: risk stratification for severity

Prevention and care of respiratory failure in obese patients

COVID-19 and Obesity: Role of Ectopic Visceral and Epicardial Adipose Tissues in Myocardial Injury

Epicardial adipose tissue: fuel for COVID-19-induced cardiac injury?

Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19

Epicardial adipose tissue, inflammatory biomarkers and COVID-19: Is there a possible relationship?

Coronavirus biology and replication: implications for SARS-CoV-2

Specific Biological Features of Adipose Tissue, and Their Impact on HIV Persistence

Adipose Tissue Dysfunction and Mafld in Obesity on the Scene of Covid-19

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients

ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet

Obesity and diabetes as comorbidities for COVID-19: Underlying mechanisms and the role of viral-bacterial interactions

Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic

The Role of the SARS-CoV-2 S-Protein Glycosylation in the Interaction of SARS-CoV-2/ACE2 and Immunological Responses

Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike

Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus

Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study

Admission fasting plasma glucose is an independent risk factor for 28-day mortality in patients with COVID-19

Requirements for CEACAMs and cholesterol during murine coronavirus cell entry

The role of high cholesterol in age-related COVID19 lethality

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions

Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

Adipokines in health and disease

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections

Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein

DPP4 deletion in adipose tissue improves hepatic insulin sensitivity in diet-induced obesity

DPP-4 inhibition and COVID-19: From initial concerns to recent expectations

Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) -A systematic review, meta-analysis, and meta-regression

Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study

A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19

Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study

Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?

Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic

Innate immunity to virus infection

Regulating the adaptive immune response to respiratory virus infection

The many faces of the anti-COVID immune response

Lessons for COVID-19 Immunity from Other Coronavirus Infections

COVID-19 and the human innate immune system

Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses -are we our own worst enemy?

Obesity, inflammation and the immune system

A guide to immunometabolism for immunologists

Germinal center B cells selectively oxidize fatty acids for energy while conducting minimal glycolysis

Immunological Mechanisms of Sickness Behavior in Viral Infection

Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2

Pattern recognition receptor-initiated innate antiviral response in mouse adipose cells

p204-Mediated innate antiviral responses in mouse adipose cells and their effects on cell functions

Toll-like receptormediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential

Dysregulation of type I interferon responses in COVID-19

Functional Roles of Pattern Recognition Receptors That Recognize Virus Nucleic Acids in Human Adipose-Derived Mesenchymal Stem Cells

Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways

Role of IFN and Complements System: Innate Immunity in SARS-CoV-2

Coronavirus virulence genes with main focus on SARS-CoV envelope gene

Obesity-Associated Alterations of Natural Killer Cells and Immunosurveillance of Cancer

Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection

Characterization of Surface Receptor Expression and Cytotoxicity of Human NK Cells and NK Cell Subsets in Overweight and Obese Humans

Physical Inactivity and Unhealthy Metabolic Status Are Associated with Decreased Natural Killer Cell Activity

Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome

Endogenous lipid antigens for invariant natural killer T cells hold the reins in adipose tissue homeostasis

Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production

Impact of Obesity on Influenza A Virus Pathogenesis, Immune Response, and Evolution

Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

Exacerbated Staphylococcus aureus Foot Infections in Obese/Diabetic Mice Are Associated with Impaired Germinal Center Reactions, Ig Class Switching, and Humoral Immunity

Changes in Nutritional Status Impact Immune Cell Metabolism and Function

Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality

Pattern Recognition Receptor-Mediated Chronic Inflammation in the Development and Progression of Obesity-Related Metabolic Diseases

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Sex hormones signal why virus hits men harder

Leptin and the central nervous system control of glucose metabolism

Inflammation during obesity is not all bad: evidence from animal and human studies

Human leptin characterization

Leptin levels in SARS-CoV-2 infection related respiratory failure: A cross-sectional study and a pathophysiological framework on the role of fat tissue

Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2

Mitochondria and Mitochondrial DNA: Key Elements in the Pathogenesis and Exacerbation of the Inflammatory State Caused by COVID-19

Mechanism of insulin resistance in obesity: a role of ATP

Inflammasome activation at the crux of severe COVID-19

Succinyl-CoA Ligase Deficiency in Pro-inflammatory and Tissue-Invasive T Cells

The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity

SUCNR1-mediated chemotaxis of macrophages aggravates obesity-induced inflammation and diabetes

Potential interventions for novel coronavirus in China: A systematic review

Obesity and vitamin D deficiency: a systematic review and meta-analysis

Potential pathophysiological mechanisms leading to increased COVID-19 susceptibility and severity in obesity

Vitamin D and coronavirus disease 2019 (COVID-19): rapid evidence review

Rapid Weight Loss, Central Obesity Improvement and Blood Glucose Reduction Are Associated with a Stronger Adaptive Immune Response Following COVID-19 mRNA Vaccine

Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t